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Genetic susceptibility is one factor that con-
tributes to the wide range of health outcomes
occurring among individuals exposed to simi-
lar levels of toxicants. The gene that encodes
the δ-aminolevulinic acid dehydratase (ALAD)
enzyme is a potentially important modiﬁer of
relations between lead exposure/dose and renal
function. The ALAD enzyme is a principal
lead-binding protein with two common alle-
les, ALAD1 and ALAD2 (Battistuzzi et al.
1981). A higher percentage of lead is bound
to the protein present in those with the
ALAD2 allele compared with those with the
ALAD1 allele (Bergdahl et al. 1997b). Several
studies have found that similarly exposed par-
ticipants with the ALAD2 allele have higher
blood lead levels than those who are homozy-
gous for the ALAD1 allele (Kelada et al. 2001;
Wetmur et al. 1991; Ziemsen et al. 1986).
Other toxicokinetic differences have also been
reported, including lower dimercaptosuccinic
acid (DMSA)-chelatable lead levels (control-
ling for exposure duration and blood lead)
(Schwartz et al. 1997) and less efficient
uptake of lead into bone, resulting in a lower
bone lead level for a given cumulative blood
lead (Fleming et al. 1998). The impact of
these differences on lead toxicity is not clear.
ALAD2 binding could prevent lead from
reaching target organs, thus reducing toxicity.
On the other hand, increased blood lead
could result in greater potential for toxicity.
Two studies have examined the impact of
ALAD genotype on the renal system; one
reported higher unadjusted mean serum crea-
tinine (p = 0.11) in participants with the
ALAD2 allele (Bergdahl et al. 1997a). The
other found higher mean serum creatinine
(p = 0.11) and blood urea nitrogen (BUN;
p = 0.03) in participants with the ALAD2
allele; however, after adjustment for covariates,
the statistical signiﬁcance of these associations
decreased (p = 0.16 for serum creatinine and
p = 0.06 for BUN) (Smith et al. 1995).
Endothelial nitric oxide synthase (eNOS)
catalyzes the transformation of L-arginine to
nitric oxide, which is a vasodilator. Animal
models of renal disease have demonstrated that
administration of L-arginine results in
decreased glomerulosclerosis and tubulointer-
stitial damage; this is thought to be mediated
via increased NO (Klahr 2001). The
Glu298Asp polymorphism of the eNOS gene
involves a G-to-T conversion at nucleotide
position 894 within exon 7, which results in
substitution of aspartic acid for glutamic acid
at codon 298. Research in patients with essen-
tial hypertension has found both an increased
frequency of the Asp allele (Miyamoto et al.
1998) and decreased NO production (Klahr
2001). Presence of the Asp allele was associated
with an earlier age at development of end-stage
renal disease in males with autosomal domi-
nant polycystic kidney disease; patients with
the Asp allele also demonstrated decreased NO
synthase activity (Persu et al. 2002). Data on
the eNOS Glu298Asp polymorphism in dia-
betic nephropathy are inconsistent; Noiri et
al. (2002) found a higher frequency of the
Asp allele in those with diabetic end-stage
renal disease; however, Zanchi et al. (2000)
did not. Noiri et al. (2002) also reported
decreased NO production with the Asp allele
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We analyzed data from 798 lead workers to determine whether polymorphisms in the genes
encoding δ-aminolevulinic acid dehydratase (ALAD), endothelial nitric oxide synthase (eNOS),
and the vitamin D receptor (VDR) were associated with or modiﬁed relations of lead exposure and
dose measures with renal outcomes. Lead exposure was assessed with job duration, blood lead,
dimercaptosuccinic acid (DMSA)-chelatable lead, and tibia lead. Renal function was assessed with
blood urea nitrogen (BUN), serum creatinine, measured creatinine clearance, calculated creatinine
clearance and urinary N-acetyl-β-D-glucosaminidase (NAG), and retinol-binding protein. Mean
(± SD) tibia lead, blood lead, and DMSA-chelatable lead levels were 37.2 ± 40.4 µg/g bone min-
eral, 32.0 ± 15.0 µg/dL, and 767.8 ± 862.1 µg/g creatinine, respectively. After adjustment, partici-
pants with the ALAD2 allele had lower mean serum creatinine and higher calculated creatinine
clearance. We observed effect modiﬁcation by ALAD on associations between blood lead and/or
DMSA-chelatable lead and three renal outcomes. Among those with the ALAD1-2 genotype,
higher lead measures were associated with lower BUN and serum creatinine and higher calculated
creatinine clearance. Participants with the eNOS variant allele were found to have higher mea-
sured creatinine clearance and BUN. In participants with the Asp allele, longer duration working
with lead was associated with higher serum creatinine and lower calculated creatinine clearance
and NAG; all were signiﬁcantly different from relations in those with the Glu/Glu genotype except
NAG (p = 0.08). No significant differences were seen in renal outcomes by VDR genotype, nor
was consistent effect modification observed. The ALAD findings could be explained by lead-
induced hyperfiltration. Key words: δ-aminolevulinic acid dehydratase, endothelial nitric oxide
synthase, genetic susceptibility factors, lead exposure, N-acetyl-β-D-glucosaminidase (NAG), renal
function, retinol-binding protein, vitamin D receptor. Environ Health Perspect 111:1613–1619
(2003). doi:10.1289/ehp.6116 available via http://dx.doi.org/ [Online 12 June 2003]
Environmental Medicine Articlein an in vitro system. In addition to its poten-
tial as a renal genetic susceptibility factor, the
eNOS gene is of interest because animal data
suggest that lead exposure also results in
decreased NO levels (Vaziri et al. 1997).
The vitamin D receptor (VDR) is impor-
tant for calcium absorption and bone miner-
alization and is activated through binding of
1,25-dihydroxyvitamin D3. The VDR BsmI
polymorphism has three genotypes resulting
from restriction enzyme digestion: bb, Bb,
and BB, with the uppercase letter signifying
the absence of the restriction site. Decreased
bone mineral density has been reported in
those with the BB compared with the bb
genotype (Cooper and Umbach 1996). In the
lead workers studied here, participants with
the B allele were found to have significantly
higher blood lead, DMSA-chelatable lead,
tibia lead (Schwartz et al. 2000a), and systolic
and diastolic blood pressure (Lee B-K et al.
2001), compared with participants with the
bb genotype. In a Caucasian population, the
b allele was significantly associated with
improved survival in renal dialysis patients
(Marco et al. 2001). In contrast, an increased
risk for renal disease in Japanese systemic
lupus erythematosus patients with the b allele
has also been reported (Ozaki et al. 2000).
Herein, we report associations of ALAD,
VDR, and eNOS polymorphisms with six
renal outcomes, and effect modification by
these polymorphisms on associations among
four lead exposure and dose measures and six
renal outcomes in a cross-sectional analysis of
Korean lead workers.
Materials and Methods
Study design and population. In this article
we focus on data obtained from 798 current
and former lead workers from the first of
three annual visits in a longitudinal study of
the neurobehavioral, peripheral nervous sys-
tem, renal, hematopoietic, and blood pressure
effects of inorganic lead exposure. All partici-
pants provided written, informed consent.
The study protocol was approved by institu-
tional review boards at the Soonchunhyang
University School of Medicine and the Johns
Hopkins University Bloomberg School of
Public Health. As previously described
(Schwartz et al. 2001; Weaver et al. 2003),
workers were recruited from 26 different
facilities, including lead battery, lead oxide,
lead crystal, and radiator manufacture, and
secondary lead smelting. Participation in the
study was voluntary, and workers were paid
approximately $30 U.S. for their time and
effort. Participation rates by plant generally
exceeded 85%. No medical exclusionary crite-
ria (e.g., blood pressure, renal disease) were
applied. Study participants were not currently
occupationally exposed to other known renal
toxicants.
Data collection. Data collection was com-
pleted either at the Institute of Industrial
Medicine of the Soonchunhyang University in
Chonan, Korea, or at the study plants, using
previously reported methods (Schwartz et al.
2001; Weaver et al. 2003). Data and biologic
specimens collected included a standardized
questionnaire on demographics, medical his-
tory, and occupational history; blood pressure
measured with a Hawksley random zero
sphygmomanometer (Lee B-K et al. 2001);
height and weight measurement; a blood spec-
imen (for blood lead, BUN, serum creatinine,
and genotyping); and a spot urine sample [for
retinol-binding protein (RBP), N-acetyl-β-D-
glucosaminidase (NAG), and creatinine], both
of which were stored at –70°C until analyzed;
and tibia lead concentration. A 4-hr urine col-
lection after oral administration of 10 mg/kg
DMSA was also obtained to measure DMSA-
chelatable lead and creatinine clearance (787
participants completed this collection).
Laboratory methods. The lead biomarkers
and renal outcomes were measured using pre-
viously reported assays (Schwartz et al. 2001;
Weaver et al. 2003). In brief, blood lead was
measured with a Hitachi 8100 Zeeman back-
ground-corrected atomic absorption spec-
trophotometer (Hitachi Ltd. Instruments,
Tokyo, Japan) with the standard addition
method of the National Institute of
Occupational Safety and Health (Kneip and
Crable 1988) at the Institute of Industrial
Medicine, a certiﬁed reference laboratory for
lead in Korea. Tibia lead was assessed with a
30-min measurement at the left mid-tibia shaft
using  109Cd K-shell X-ray fluorescence
(Schwartz et al. 1999; Todd and McNeill
1993; Todd et al. 1992). All point estimates,
including negative values, were retained in the
statistical analyses in order to minimize bias and
avoid censoring of data (Kim et al. 1995).
Urine lead levels in the 4-hr collection were
measured at the Wadsworth Center of the New
York State Department of Health (Albany, NY,
USA) by electrothermal atomic absorption
spectrometry with Zeeman background correc-
tion (model 4100ZL; Perkin-Elmer, Norwalk,
CT, USA) (Parsons and Slavin 1999).
BUN and serum creatinine were mea-
sured via an Automatic Chemical Analyzer
(TBA 40FR Biochemical Analyzer; Toshiba,
Tokyo, Japan). Urine creatinine was mea-
sured in spot samples, for adjustment of NAG
and RBP, and in the 4-hr sample after
DMSA, for determination of measured creati-
nine clearance and adjustment of DMSA-
chelatable lead levels, using a modiﬁcation of
the Sigma kit (Creatinine test kit 555A;
Sigma Chemical Co., St. Louis, MO, USA)
(Weaver et al. 2000). Measured creatinine
clearance was defined as [(urinary creatinine
in milligrams per deciliter × urine volume in
milliliters) ÷ serum creatinine in milligrams
per deciliter] × collection time in minutes.
Calculated creatinine clearance was obtained
from the Cockcroft and Gault (1976) equa-
tion. NAG was measured using the P.P.R.
NAG Test kit (P.P.R. Diagnostics Ltd.,
London, UK), which uses 2-methoxy-4-(2´-
nitrovinyl)-phenyl 2-acetamido-2-deoxy-β-D-
glucopyranoside as the substrate, resulting in
2-methoxy-4-(2´-nitrovinyl)-phenol forma-
tion after hydrolysis by NAG (Yuen et al.
1984). RBP was measured using a modiﬁca-
tion of the method of Topping et al. (1986).
For genotyping, DNA was isolated from
whole blood samples using the QIAamp
Blood Kit (QIAGEN, Hilden, Germany),
and all assays were based on polymerase chain
reaction (PCR). The protocol for ALAD
genotyping has been previously described
(Schwartz et al. 1995; Wetmur et al. 1991;
Ziemsen et al. 1986). In brief, the initial
ampliﬁcation, using 3´ and 5´ oligonucleotide
primers (5´-AGACAGACATTAGCTCA-
GTA-3´) and (5´-GGCAAAGAACACGTC-
CATTC-3´), generated a 916 base pair (bp)
fragment. A second round of amplification
using a pair of nested primers [provided by J.
Wetmur (Mount Sinai School of Medicine,
New York, NY, USA); sequences 5´-
CAGAGCTGTTCCAACAGTGGA-3´ and
5´-CCAGCACAATGTGGGAGTGA-3´,
respectively] generated an 887 bp fragment.
The amplified fragment was cleaved at the
diagnostic Msp1 site, present only in the
ALAD2 allele.
The Glu298Asp polymorphism was deter-
mined by a modiﬁcation of the assay of Hibi et
al. (1998). The primer sequences were 5´-
TCCCTGAGGAGGGCATGAGGCT-3´
and 5´-TGAGGGTCACACAGGTTCCT-3´,
which resulted in a 457 bp PCR ampliﬁcation
product. Subsequent digestion with BanII
cleaved this into two fragments (137 bp and
320 bp) in G-variant individuals who have the
BanII restriction enzyme digest site. Fragments
were resolved on a 1.5% agarose gel (with 0.2%
Synergel; Diversified Biotech, Boston, MA,
USA) and stained with ethidium bromide.
As previously published (Schwartz et al.
2000b), the VDR BsmI polymorphic site in
intron 8 was ampliﬁed using primers originat-
ing in exon 7 (primer 1: 5´-CAACCAAGAC-
TACAAGTACCGCGTCAGTGA-3´) and
intron 8 (primer 2: 5´-AACCAGCGGGAA-
GAGGTCAAGGG-3´). Participants homozy-
gous for the presence of the BsmI restriction
site are designated bb, heterozygotes are desig-
nated Bb, and those homozygous for the
absence of the site are designated BB.
Statistical analysis. The primary goals of
the analysis were a) to examine associations
between ALAD, VDR, and eNOS genotypes
and six renal outcomes (BUN, serum creati-
nine, measured creatinine clearance, calcu-
lated creatinine clearance, RBP, and NAG) in
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and b) to evaluate whether ALAD, VDR, and
eNOS genotypes modified associations
between one lead exposure measure (job dura-
tion) and three lead dose biomarkers (tibia
lead, blood lead, DMSA-chelatable lead) and
the renal outcomes. Statistical analysis was
completed using SAS statistical software pro-
grams (SAS Institute, Inc., Cary, NC, USA).
Initially, variable distributions were exam-
ined. The distributions of NAG and RBP evi-
denced departures from normality and were
thus ln (base 2)-transformed. The adequacy of
ln-transformation of these measures was con-
firmed by verification that distributions of
residuals after linear regression modeling were
normal. Linear regression modeling with a
dichotomous genotype variable was used to
compare renal outcome measures by genotype,
while controlling for the same covariates used
in the ﬁnal models. For ALAD genotype, par-
ticipants with ALAD1-2 were compared with
participants with ALAD1-1. Because of small
numbers, all analyses combined homozygous
and heterozygous variant genotype carriers for
VDR (BB and Bb) and eNOS (Glu/Asp and
Asp/Asp), unless noted otherwise.
Linear regression modeling, with cross-
product terms for genotypes and lead variables,
was used to evaluate effect modification by
genotype on associations between lead meas-
ures and renal outcomes. Covariate selection
for ﬁnal regression models used a priori vari-
ables [age, sex, body mass index (BMI; deﬁned
as weight in kilograms divided by the square
of height in meters)] and a dichotomous vari-
able for current versus former worker status to
adjust for differences between these two
groups (the former workers were older, had
lower mean blood and DMSA-chelatable lead
levels, had longer job durations, and a greater
proportion were women) as well as biologi-
cally directed stepwise forward modeling to
identify other significant variables, as previ-
ously described (Weaver et al. 2003).
Covariates in the model for clinical renal out-
comes (BUN, serum creatinine, measured
creatinine clearance, and calculated creatinine
clearance) included age, sex, BMI, hyperten-
sion, work status (current vs. former worker),
and a dichotomous variable for current smok-
ing. Models of NAG and RBP were adjusted
for age, sex, BMI, systolic blood pressure,
work status, diabetes mellitus, and alcohol
consumption.
Models were evaluated for linear regres-
sion assumptions and the presence of outlying
points using jackknife residual (Kleinbaum et
al. 1998) and added variable plots (Weisberg
1985). The latter plots are graphical sum-
maries of the relation between Y and a particu-
lar X (referred to as Xa below) adjusted for all
the other covariates. Speciﬁcally, the residuals
of the regression of Y on all the covariates
except Xa are plotted on the y-axis. This is the
part of Y not explained by those covariates.
Next, the residuals from the regression of Xa
on all the other covariates are plotted on the
x-axis. This is the part of Xa not explained by
the other covariates. The regression line and a
line determined by a scatter plot smoothing
method that calculates a locally weighted least-
squares estimate for each point in the scatter
plot (Cleveland 1979) were displayed. We
used the lowess function in the S-Plus statisti-
cal software (MathSoft, Seattle, WA, USA) to
produce these plots. When warranted, outliers
were removed and the models were repeated.
Results
A total of 79 (9.9%) participants were het-
erozygous for the ALAD2 allele, and none was
homozygous (Table 1). For VDR, 85 (10.7%)
were genotype Bb, and four (0.5%) were BB.
For eNOS, 114 (14.4%) participants were
genotype Glu/Asp, and six (0.7%) were
Asp/Asp. Mean (± SD) crude values for demo-
graphic, exposure, and outcome variables by
genotype are presented in Table 1, and
adjusted differences are noted below.
ALAD. After removal of previously iden-
tiﬁed outliers (Weaver et al. 2003) and adjust-
ment for age, sex, BMI, hypertension, current
smoking, work status (current vs. former lead
worker), and lead dose, workers with the
ALAD1-2 genotype were found to have lower
serum creatinine and higher calculated creati-
nine clearances compared with those with the
ALAD1-1 genotype (p < 0.05).
Effect modiﬁcation by ALAD on relations
between lead and the renal outcomes was
observed (Table 2). Among participants with
the ALAD1-2 genotype, higher lead measures
were associated with lower BUN, serum crea-
tinine, and RBP and with higher creatinine
clearances; these relations were statistically dif-
ferent (p < 0.1) compared with those in partic-
ipants with the ALAD1-1 genotype. Added
variable plots of associations between blood
lead and the renal outcomes indicate that
these relations are not due to inﬂuential out-
liers (Figure 1). These plots also illustrate the
magnitude of change in the renal outcomes
across the blood lead range in those with the
ALAD2 allele. No blood lead level threshold
for these effects is apparent.
To determine whether increased urinary
creatinine from increased glomerular ﬁltration
contributed to the association between higher
blood lead and lower RBP in those with the
ALAD1-2 genotype, the model was repeated
using RBP unadjusted by creatinine. The β
coefﬁcient was similar (–0.0123), and p = 0.09.
eNOS. After removal of previously identi-
ﬁed outliers (Weaver et al. 2003) and adjust-
ment, mean measured creatinine clearance was
found to be higher in participants with the
eNOS Asp allele (p < 0.05). Mean measured
creatinine clearance, adjusted for age, sex,
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Table 1. Selected demographic, exposure, and outcome variables by ALAD, eNOS, and VDR genotype in Korean lead workers.a
ALAD genotype eNOS genotype VDR genotype
Characteristic 1–1 1-2 Glu/Glu Asp/Glu or Asp/Asp bb Bb or BB
Number (%) 716 (90.1) 79 (9.9) 673 (84.9) 120 (15.1) 709 (88.8) 89 (11.2)
Age, years (mean ± SD) 40.5 ± 10.2 40.1 ± 9.7 40.3 ± 10.1 41.1 ± 10.1 40.2 ± 10.1 42.7 ± 10.3
Sex, n (%)
Male 569 (79.5) 62 (78.5) 537 (79.8) 93 (77.5) 572 (80.7) 62 (69.7)
Female 147 (20.5) 17 (21.5) 136 (20.2) 27 (22.5) 137 (19.3) 27 (30.3)
BMI, kg/m2 (mean ± SD) 23.1 ± 3.0 22.3 ± 2.6 23.1 ± 3.0 22.7 ± 2.8 22.9 ± 2.9 23.9 ± 3.4
Hypertension, n (%) 52 (7.3) 5 (6.3) 51 (7.6) 7 (5.8) 47 (6.6) 11 (12.4)
Lead job duration, years (mean ± SD)  8.1 ± 6.6 7.9 ± 5.8 8.0 ± 6.6 8.5 ± 6.5 8.2 ± 6.7 7.1 ± 5.6
Blood lead, µg/dL (mean ± SD) 31.7 ± 14.9 34.2 ± 15.9 32.0 ± 15.1 31.2 ± 14.6 31.6 ±14.8 34.8 ± 16.1
Tibia lead, µg Pb/g bone mineral (mean ± SD) 37.5 ± 40.6 31.4 ± 29.5 37.5 ± 41.6 35.8 ± 34.0 37.1 ± 41.2 38.1 ± 33.5
DMSA-chelatable lead, µg Pb/g creatinine (mean ± SD) 763.2 ± 822.4 838.2 ± 1188.3 775.2 ± 899.7 717.9 ± 622.8 750.2 ± 873.9 925.7 ± 758.5
BUN, mg/dL (mean ± SD) 14.5 ± 3.6 13.7 ± 3.9 14.3 ± 3.6 14.9 ± 3.8* 14.4 ± 3.7 14.4 ± 3.3
Serum creatinine, mg/dL (mean ± SD) 0.90 ± 0.15 0.86 ± 0.12** 0.90 ± 0.16 0.89 ± 0.13 0.90 ± 0.16 0.89 ± 0.13
Measured creatinine clearance, mL/min (mean ± SD) 114.6 ± 34.2 115.6 ± 27.6 113.7 ± 32.9 118.8 ± 36.3** 115.0 ± 33.7 111.8 ± 33.5
Calculated creatinine clearance, mL/min (mean ± SD) 94.6 ± 20.7 95.7 ± 19.7** 94.6 ± 20.0 94.1 ± 22.6 94.6 ± 20.3 94.8 ± 23.3
NAG, µmol/hr/g creatinine (mean ± SD) 229.7 ± 248.6 204.6 ± 141.6 221.5 ± 239.5 259.6 ± 244.5 226.1 ± 244.5 229.3 ± 200.1
RBP, µg/g creatinine (mean ± SD) 57.2 ± 101.1 65.6 ± 89.5 63.7 ± 204.7 61.7 ± 87.8 64.7 ± 201.7 55.8 ± 60.3
aALAD, eNOS, and VDR genotyping were completed on 795, 793, and 798 lead workers, respectively. *p < 0.1 for difference between renal outcomes by genotype after adjustment.
**p < 0.05 for difference between renal outcomes by genotype after adjustment.BMI, hypertension, work status (current vs.
former), current smoking, and blood lead, was
112.3 mL/min in participants with the
Glu/Glu genotype, 118.2 mL/min in those
with Glu/Asp genotype, and 125.4 mL/min in
the ﬁve participants with the Asp/Asp genotype
(p = 0.02 for trend). In contrast, BUN was also
higher (p = 0.04–0.06 depending on lead
covariate in the model), and a trend was pre-
sent for mean BUN by genotype (p = 0.04);
means after adjustment for the same covariates,
except tibia instead of blood lead, were 14.2,
14.9, and 15.8 µg/dL for the Glu/Glu, Glu/Asp,
and Asp/Asp genotypes, respectively. Effect
modification by eNOS on relations between
lead and the renal outcomes was observed in
only 3 of 24 models (Table 2). Among partici-
pants with the Glu/Glu genotype, longer lead
job duration was associated with higher calcu-
lated creatinine clearance but also borderline
associated (p = 0.08) with higher NAG. In
contrast, in those with the Asp allele, longer
lead job duration was associated with higher
serum creatinine and lower calculated creati-
nine clearance but also lower NAG. These rela-
tions were statistically different (p < 0.05
except for NAG, where p < 0.1) and in oppo-
site directions compared with those in partici-
pants with the Glu/Glu genotype.
VDR. No main effects of VDR genotype
on renal outcomes were observed. Effect modi-
fication was present in 2 of 24 models
(Table 2). Higher tibia lead was associated with
higher measured creatinine clearance in all par-
ticipants, but the slope of the relation was
greater in those with VDR Bb or BB genotypes.
DMSA-chelatable lead was directly associated
with NAG only in those with the bb genotype.
Discussion
In this study, we evaluated whether polymor-
phisms in three genes (ALAD, VDR, and
eNOS) were associated with or modiﬁed rela-
tions of lead exposure and dose measures with
six renal outcomes in a large cross-sectional
study of Korean lead workers. To our knowl-
edge, this is the first study to evaluate effect
modification by ALAD, VDR, or eNOS
genetic polymorphisms on the relations
between lead measures and renal outcomes.
After adjustment, participants with the
ALAD2 allele had lower mean serum creati-
nine and higher calculated creatinine clear-
ance. Effect modification by ALAD on
associations between lead dose and renal out-
comes was present. Higher lead dose was asso-
ciated with lower BUN, serum creatinine,
and RBP but higher creatinine clearances in
participants with the ALAD1-2 genotype.
Mean renal outcome differences by ALAD
genotype were relatively small in magnitude,
despite being statistically significant.
However, examination of effect modiﬁcation
by ALAD revealed that, in those with the
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Table 2. Linear regression modeling of effect modiﬁcation by genotype on selected associations between
renal outcomes and lead dose variables.
Variable β coefﬁcient SE β p-Value
BUN (mg/dL)
Intercept 9.6098  1.1686  <  0.01
ALAD1-2 2.0037 1.0164  0.05
Blood lead (µg/dL) 0.0094  0.0102  0.36
Blood lead × ALAD1-2 –0.0771 0.0278  <  0.01
Intercept 9.5556  1.1701  <  0.01
ALAD1-2 0.8670 0.6672  0.19
DMSA-chelatable lead (µg Pb/g creatinine) 0.0000  0.0002  0.93
DMSA-chelatable lead × ALAD1-2 –0.0022 0.0008 <  0.01
Serum creatinine (mg/dL)
Intercept 0.8472  0.0358  <  0.01
ALAD1-2 0.0222 0.0316  0.48
Blood lead (µg/dL) 0.0003  0.0003  0.41
Blood lead × ALAD1-2 –0.0017 0.0009  0.05
Intercept 0.8519  0.0361  <  0.01
ALAD1-2 0.0076 0.0205  0.71
DMSA-chelatable lead (µg Pb/g creatinine) –0.0000  0.0000  0.02
DMSA-chelatable lead × ALAD1-2 –0.0001 0.0000  0.02
Intercept 0.8507  0.0362  <  0.01
eNOS Asp/Glu or Asp/Asp –0.0364 0.0173  0.04
Lead job duration (years)  –0.0009  0.0007  0.25
Lead job duration × eNOS Asp/Glu or Asp/Asp 0.0039 0.0016  0.02
Measured creatinine clearance (mL/min)
Intercept 74.0404  9.2094  <  0.01
ALAD1-2 –2.2897 5.2482  0.66
DMSA-chelatable lead (µg Pb/g creatinine) –0.0010  0.0016  0.53
DMSA-chelatable lead × ALAD1-2 0.0106 0.0061  0.08
Intercept 77.4254  9.0917  <  0.01
VDR Bb or BB –9.7894 5.2827  0.06
Tibia lead (µg Pb/g bone mineral) 0.0514  0.0290  0.08
Tibia lead × VDR Bb or BB 0.2419 0.1229  0.05
Calculated creatinine clearance (mL/min)
Intercept 56.6738  4.3455  <  0.01
ALAD1-2 –6.3221 3.7759  0.09
Blood lead (µg/dL) –0.0567  0.0383  0.14
Blood lead × ALAD1-2 0.2875 0.1033  <  0.01
Intercept 56.2870  4.3876  <  0.01
ALAD1-2 –2.2172 2.4992  0.38
DMSA-chelatable lead (µg Pb/g creatinine) 0.0005  0.0007  0.49
DMSA-chelatable lead × ALAD1-2 0.0079 0.0029  <  0.01
Intercept 56.6014  4.3343  <  0.01
eNOS Asp/Glu or Asp/Asp 5.0939 2.0672  0.01
Lead job duration (years) 0.2401  0.0898  0.01
Lead job duration × eNOS Asp/Glu or Asp/Asp –0.4015  0.1957  0.04
ln NAG [ln (µmoL/hr/g creatinine)] models
Intercept 4.0771  0.2156  <  0.01
eNOS Asp/Glu or Asp/Asp 0.2254 0.0931  0.02
Lead job duration (years) 0.0070  0.0040  0.08
Lead job duration × eNOS Asp/Glu or Asp/Asp –0.0157 0.0088  0.08
Intercept 4.1184  0.2130  <  0.01
VDR Bb or BB 0.1528 0.1014  0.13
DMSA-chelatable lead (µg Pb/g creatinine) 0.0002  0.0000  < 0.01
DMSA-chelatable lead × VDR Bb or BB –0.0002 0.0001  0.05
ln RBP [ln (µg/g creatinine)]
Intercept 2.6393  0.2615  <  0.01
ALAD1-2 0.4919 0.2085  0.02
Blood lead (µg/dL) 0.0033  0.0021  0.12
Blood lead × ALAD1-2 –0.0112 0.0057  0.05
BUN, serum creatinine, measured creatinine clearance, and calculated creatinine clearance models were also adjusted for
age, sex, BMI, current/former exposure status, current smoking, and hypertension. NAG and RBP models were adjusted for
age, sex, BMI, systolic blood pressure, current/former exposure status, current alcohol ingestion, and diabetes. p-Values for
the cross-product terms reﬂect the statistical signiﬁcance of the difference between the slopes of the regression line for the
gene variant group and the regression line for the reference gene group. Slopes in the nonreference category are obtained
by adding the β coefﬁcient of the cross-product term to the β coefﬁcient for the reference category. Only outcomes with sig-
niﬁcant or borderline signiﬁcant associations (p < 0.1) are presented from a total of 24 models for each gene.ALAD2 allele, clinical renal outcomes changed
by 10% or more across the blood lead range.
The prevalence of the ALAD2 allele is
approximately 20% in Caucasians and 10% in
Asians (Kelada et al. 2001; Schwartz et al.
1995). In addition to the toxicokinetic differ-
ences mentioned above, lower cortical bone
lead (Hu et al. 2001) has been reported. Hu et
al. (2001) also noted less efficient uptake of
lead into bone when trabecular lead levels
>6 0µ g/g bone mineral were present. Data on
the health implications of these toxicokinetic
differences suggest a protective effect of the
ALAD2 allele on the hematologic system
(Alexander et al. 1998; Schwartz et al. 1995;
Sithisarankul et al. 1997). In the lead workers
studied here, those with the ALAD2 allele had
lower levels of zinc protoporphyrin and plasma
aminolevulinic acid, but there was no clear
effect modiﬁcation by ALAD genotype on rela-
tions between lead dose and hematologic sys-
tem outcomes (Lee SS et al. 2001). Possibly
improved neuropsychologic function has also
been reported, based on a few participants with
the variant allele (Bellinger et al. 1994).
Two studies have assessed the effect of
ALAD genotype on the renal system in lead-
exposed populations. Smith et al. (1995)
studied 691 volunteers from a construction
trade union, of whom 96 had the ALAD2
allele. Mean blood lead was 7.78 µg/dL. As
described above, BUN and serum creatinine
were elevated in participants with the ALAD2
allele compared with those with the ALAD1-1
genotype, but p-values for these differences
increased after adjustment. Bergdahl et al.
(1997a) assessed the impact of ALAD geno-
type on kidney function in 89 lead workers,
of whom only seven had the ALAD2 allele.
Serum creatinine was elevated in the latter
group, although, again, the difference was not
statistically signiﬁcant and adjusted data were
not presented. Thus, our results are not con-
sistent with the data presented in these publi-
cations. There are some potentially important
differences between our work and these stud-
ies. The small number of participants with
the ALAD2 allele limits the power to detect a
difference in the study of Bergdahl et al.
(1997a). Compared with Smith et al. (1995),
our participants had a higher mean blood lead
level and a wider range of lead measures and
renal outcomes. These factors may play a role
in the differences noted.
Our work expands on the existing litera-
ture pertaining to the effect of ALAD genotype
on the renal system in lead-exposed popula-
tions by assessing effect modification.
Although our data by ALAD genotype are
unique, inverse associations similar to those we
found in participants with ALAD2 allele (i.e.,
associations between higher lead measures and
lower BUN and serum creatinine and higher
creatinine clearances) have been previously
reported in lead-exposed populations. Mean
measured creatinine clearance was 112.9
mL/min/1.73 m2 in 22 adults who had experi-
enced childhood lead poisoning, compared
with 88.8 mL/min/1.73 m2 in age- and sex-
matched controls (p < 0.01) (Hu 1991). Roels
et al. (1994) also reported a mean creatinine
clearance of 121.3 mL/min/1.73 m2 in a group
of 76 lead workers compared with 115.5
mL/min/1.73 m2 in 68 age- and sex-matched
controls (p < 0.05). More important, they also
observed a positive association between tibia
lead and creatinine clearance. Similarly, we also
found associations in the population studied
here between higher lead measures and lower
BUN and serum creatinine, and higher creati-
nine clearance measures, especially in younger
workers (Weaver et al. 2003).
A longitudinal study in rodents reported a
positive association between glomerular ﬁltra-
tion rate (GFR) and blood lead after 3 months
of lead acetate ingestion (Khalil-Manesh et al.
1992). However, after 6 months of exposure,
tubulointerstitial fibrosis was present, and at
12 months, focal glomerulosclerosis was seen
and signs of renal insufﬁciency had developed.
A similar pattern of renal function change has
been observed in studies of human diabetics
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Figure 1. Added variable plots of the effect modiﬁcation by ALAD on relations between blood lead and four
renal outcomes in 795 Korean lead workers. (A, C, E, G) Data from participants with the ALAD1-1 genotype.
(B, D, F, H) Data from those with ALAD1-2. (A, B) Adjusted BUN. (C, D) Adjusted serum creatinine. (E, F)
Adjusted calculated creatinine clearance. (G, H) Adjusted RBP. For each plot, the adjusted regression line
(dashed) and the lowess line (solid; see “Materials and Methods” for details) are shown. Both have been
adjusted for covariates. For ease of interpretation, axes have been scaled so that the plotted residuals are
centered around the means rather than zero.
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ALAD1-1 ALAD1-2followed longitudinally; supranormal creati-
nine clearance early in the clinical course of
type I diabetes is a predictor of subsequent
nephropathy (Brenner et al. 1996). Other dis-
eases and conditions in which increased
glomerular ﬁltration is present, such as sickle
cell disease and obesity, are also associated
with an increased risk for subsequent renal
abnormalities (Allon 1990; Nenov et al.
2000). The hyperﬁltration theory, involving a
paradoxical initial increase in GFR associated
with glomerular hypertension and ultimately
ending in glomerulosclerosis and renal failure,
is one mechanistic explanation for this pattern
(Brenner et al. 1996). However, kidney
donors also have elevated GFR but generally
do not have evidence of other renal abnormal-
ities. These individuals are carefully screened
to exclude underlying diseases that could
result in adverse renal outcomes, a fact that
may, in part, explain this observation (Nenov
et al. 2000). It is also possible that the signiﬁ-
cance of increased creatinine clearance may
vary depending on the underlying condition.
The hyperﬁltration theory generally refers
to clinical renal function. The effect modiﬁca-
tion by ALAD genotype on relations between
blood lead and RBP, a renal early biologic
effect marker, is another novel and intriguing
ﬁnding in this population. One possible expla-
nation for this ﬁnding is that RBP is routinely
divided by urinary creatinine to reduce the
impact of urinary dilutional variation on its
concentration. However, in the setting of
increased glomerular ﬁltration, urinary creati-
nine may also be increased, which adversely
affects the accuracy of spot urine creatinine-
adjusted biomarker results (Muller et al.
1999). We were able to exclude this as an
explanatory factor in our ﬁndings by modeling
with unadjusted RBP.
After adjustment, we found that partici-
pants with the eNOS Asp allele had higher
measured creatinine clearance but, paradoxi-
cally, higher BUN, with signiﬁcant trend tests
for both across the three eNOS genotype
groups (none, one, and two Asp alleles). Effect
modiﬁcation by eNOS was present in only 3
of 24 models and, although the two signifi-
cant associations suggested increased risk for
adverse renal outcomes with higher lead dose
in those with the Asp allele, the borderline
association with NAG was inconsistent.
Reported Asp allele frequencies of the
Glu298Asp polymorphism in two Japanese
populations were 5.0% and 8.7% (Hibi et al.
1998; Miyamoto et al. 1998); a frequency of
32% was reported in a U.S. population of
unspecified ethnicity (Zanchi et al. 2000).
Data on this polymorphism are still relatively
limited; however, as discussed above, recent
work suggests that the Asp allele may be asso-
ciated with decreased serum NO levels.
Because lead-induced hypertension in rats is
also associated with reduced urinary excretion
of NO metabolites (Vaziri et al. 1997), the
combination of the Asp allele and lead expo-
sure may confer an increased risk for lead-
induced renal disease via vasoconstriction.
Although some of our ﬁndings are consistent
with this, our ability to draw ﬁrm conclusions
based on our data is limited by their lack of
consistency. Similarly, we found few signifi-
cant results for VDR, despite the previously
mentioned lead measure and blood pressure
differences reported in this same population.
It is possible that our relative lack of positive
findings with eNOS and VDR genotypes is
because the effect of lead dose on the kidney
is not mediated through either of these genes.
However, it must also be noted that, although
the sample size was large, the number of par-
ticipants with variant alleles was relatively
small, leading to unstable estimation of coefﬁ-
cients. Further research is needed to deter-
mine which genetic susceptibility factors,
other than ALAD, are important for the effect
of lead on the renal system.
In conclusion, higher lead dose was associ-
ated with lower BUN, serum creatinine, and
RBP but higher creatinine clearances in partic-
ipants with the ALAD1-2 genotype. These
ﬁndings may represent lead-induced hyperﬁl-
tration. Longitudinal data will be important
in determining whether subsequent renal
function decline differs by genotype.
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